umbralisib   Click here for help

GtoPdb Ligand ID: 8916

Synonyms: example A1 [US2014011819] | RP-5264 | RP5264 | TGR-1202 | TGR1202 | Ukoniq®
Approved drug Immunopharmacology Ligand
umbralisib is an approved drug (FDA (2021))
Compound class: Synthetic organic
Comment: Umbralisib (TGR-1202; RP5264,) is an orally available, selective inhibitor of the δ isoform of phosphoinositide 3-kinase (PI3K) [1,3,5], that was developed by TG Therapeutics for the treatment of several B cell malignancies. It also inhibits casein kinase-1ε [2]. For clinical application umbralisib is formulated as the tosylate salt.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 109.06
Molecular weight 571.18
XLogP 8.24
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(Oc1ccc(cc1F)c1nn(c2c1c(N)ncn2)C(c1oc2ccc(cc2c(=O)c1c1cccc(c1)F)F)C)C
Isomeric SMILES CC(Oc1ccc(cc1F)c1nn(c2c1c(N)ncn2)[C@H](c1oc2ccc(cc2c(=O)c1c1cccc(c1)F)F)C)C
InChI InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
InChI Key IUVCFHHAEHNCFT-INIZCTEOSA-N
Bioactivity Comments
Umbralisib is >1000-fold selective against PI3Kα, >54-fold selective against PI3Kβ and >9-fold selective against PI3Kγ [5]. It also inhibits casein kinase-1ε (CSNK1E; by 60% at 1 μM), which is a major regulator of protein translation [3].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
casein kinase 1 epsilon Hs Inhibitor Inhibition 5.2 pEC50 - 3
pEC50 5.2 (EC50 6x10-6 M) [3]
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Primary target of this compound Hs Inhibitor Inhibition 7.9 pIC50 - 5
pIC50 7.9 (IC50 1.383x10-8 M) [5]